Citrus Flavone Tangeretin Inhibits CRPC Cell Proliferation by Regulating Cx26, AKT, and AR Signaling.
Citrus Flavone Tangeretin Inhibits CRPC Cell Proliferation by Regulating Cx26, AKT, and AR Signaling.
复制标题
柑橘黄酮橘皮素通过调节 Cx26、AKT 和 AR 信号传导抑制 CRPC 细胞增殖
DOI:
10.1155/2022/6422500
复制
发表时间:
2022
期刊:
影响因子:
--
通讯作者:
Lai Y
中科院分区:
文献类型:
--
作者:
Zhang N;Wu W;Huang Y;An L;He Z;Chang Z;He Z;Lai Y
Prostate cancer (PCa) progression depends on the action of androgen receptors (AR). Therefore, preventing ligand-mediated activation of AR is the first-line treatment strategy for metastatic PCa. Androgen deprivation therapy (ADT) can inhibit ligand binding to AR and alleviate PCa progression initially. However, due to the adaptation of PCa and recovery of AR signaling, castration-resistant prostate cancer (CRPC) eventually develops. Exploring novel dietary compounds that can target AR signaling appears to be a viable alternative therapeutic option for CRPC. In the present study, compounds from the citrus fruits were focused upon, which contain various flavonoid ingredients. Key components contained within orange peel, which is frequently used in traditional Chinese medicine, and downstream targets were first analyzed using network pharmacology approach. Notably, it was found that tangeretin, an active ingredient from orange peel, can significantly inhibit CRPC cell (C4-2 and Du145 cells) proliferation and migration whilst also synergistically increasing the sensitivity of CRPC cells to anti-tumor drugs sorafenib or cisplatin. Tangeretin also significantly reduced AR and AKT expressions in C4-2 cells and signal transducer and activator of transcription 3 expression in the androgen-insensitive cell line Du145. In addition, tangeretin increased the expression of both connexin26 (Cx26) and gap junction function, which may mediate the bystander effects of cisplatin or sorafenib. Taken together, the present study revealed a novel molecular mechanism by which tangeretin may inhibit the proliferation of CRPC cells, by affecting the Cx26/AKT/AR pathway, to synergistically increase the sensitivity of CRPC cells to sorafenib and cisplatin.
登录
查看更多内容
影响因子:
6.4
作者:
Kou, Yu;Ji, Liyan;Lu, Linlin
通讯作者:
Lu, Linlin
影响因子:
5.6
作者:
Lai, Yongchang;Liang, Xiongfa;Wu, Wenqi
通讯作者:
Wu, Wenqi
影响因子:
4
作者:
Lim, Whasun;Park, Sunwoo;Song, Gwonhwa
通讯作者:
Song, Gwonhwa
影响因子:
11.8
作者:
de Vries, Gerda;Rosas-Plaza, Ximena;de Jong, Steven
通讯作者:
de Jong, Steven
影响因子:
5.5
作者:
Mulkearns-Hubert EE;Reizes O;Lathia JD
通讯作者:
Lathia JD